Related Experiment Video
Updated: Jun 21, 2026
Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
Published on: July 18, 2019
Effects of Fructose on Features of Steatotic Liver Disease in HepG2 Cells
Matthew Thomas Howes1, Jessie King1, Rhonda Joy Rosengren1
1Department of Pharmacology and Toxicology, University of Otago, Dunedin 9016, New Zealand.
Background/Objectives:
Metabolic (dysfunction)-associated steatotic liver disease (MASLD), the hepatic consequence of metabolic syndrome, affects 30% of the global population. Studies in animals and humans investigating the effect of fructose on MASLD present conflicting findings, while in vitro methods often fail to add meaningful evidence due to acute exposures (<72 h) and non-physiological concentrations. This study aimed to determine the effect of fructose on triglyceride (TG) accumulation in HepG2 cells following acute and chronic exposures and assess its effect on the expression of genes related to de novo lipogenesis (DNL).
Methods:
TG concentration was measured after 48 h in response to fructose (20 mM) or glucose (20 mM), with or without a fatty acid mixture (oleic acid/palmitic acid 110 µM/55 µM), in low (5.5 mM)- and high (25.5 mM)-glucose media. To model chronic exposure, cells were maintained in fructose, glucose, or fatty acids for 28 days and the TG concentration was determined every 7 days. The effect of fructose on DNL regulators (SREBPF1, NR1H3, FASN, and ACACA) was determined using qPCR.
Results:
Neither fructose nor glucose, with or without fatty acids, changed the TG levels in cells at 48 h and the media glucose concentration had no effect on this result. Similarly, fructose did not increase TG levels after 28 days. While fructose and glucose did not affect key DNL genes at 6 h, the fatty acid mixture reduced FASN by 41%.
Conclusions:
This study shows that fructose did not significantly impact TG synthesis or DNL gene expression in the HepG2 cell model. Future studies should consider using primary human hepatocytes or more complex in vitro models.
Insights
This study found that fructose did not increase triglyceride accumulation or affect de novo lipogenesis genes in liver cells. Further research with human cells is recommended for MASLD insights.
Area of Science:
- Hepatology
- Metabolic Disease Research
- Cell Biology
Background:
- Metabolic (dysfunction)-associated steatotic liver disease (MASLD) affects 30% of the global population.
- Existing research on fructose's impact on MASLD yields conflicting results.
- In vitro studies often use non-physiological conditions, limiting their relevance.
Purpose of the Study:
- To investigate the effect of fructose on triglyceride accumulation in HepG2 cells.
- To assess fructose's impact on de novo lipogenesis (DNL) gene expression.
- To compare acute and chronic exposure effects of fructose.
Main Methods:
- HepG2 cells were exposed to fructose or glucose with/without fatty acids for 48 hours and 28 days.
- Triglyceride levels were measured at various time points.
- Quantitative PCR (qPCR) was used to analyze DNL gene expression (SREBPF1, NR1H3, FASN, ACACA).
Main Results:
- Neither acute nor chronic fructose exposure significantly increased triglyceride levels in HepG2 cells.
- Fructose and glucose did not alter key de novo lipogenesis gene expression at 6 hours.
- Fatty acid mixtures, however, reduced FASN expression by 41%.
Conclusions:
- Fructose did not significantly induce triglyceride synthesis or alter DNL gene expression in this HepG2 cell model.
- The findings suggest fructose may not be a primary driver of steatosis in this specific in vitro setting.
- Future research should utilize primary human hepatocytes or more complex models for greater physiological relevance.
More Related Videos
08:35A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
Published on: May 18, 2021
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
